Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-basedCOVID-19 vaccine.[1] It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein.[1] Self-amplifying means that the mRNA also carries instructions to make a protein called replicase.[1]
Kostaive was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved.[2][3]
Medical uses
Zapomeran is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus.[1]
Society and culture
Legal status
Kostaive was approved for medical use in Japan in November 2023.[4][5][6]
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults.[1] The applicant for this medicinal product is Arcturus Therapeutics Europe B.V.[1]
^ abcdef"Kostaive EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 16 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^World Health Organization (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 89". WHO Drug Information. 37 (1). hdl:10665/366661.
^World Health Organization (2024). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 91". WHO Drug Information. 38 (1). hdl:10665/378096.
.svg){kind=small}
